Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ribOvax Biotechnologies (Ribovax) has given license for its patented SEBVI Technology to PX'Therapeutics (PX'T) to discover and develop human monoclonal antibodies.
Subscribe to our email newsletter
SEBVI Technology uses Epstein Barr Virus for immortalizing and isolating circulating human B cells from the blood of immunocompetent individuals which secrete antigen-specific IgG antibodies.
PX’T plans to utilize the SEBVI technological platform for providing an expanded range of services in the field of human monoclonal antibody development and production for diagnostic and therapeutic applications.
Ribovax member of board of directors Mikhail Sazonov said
Mikhail Sazonov, member of the Ribovax Biotechnologies SA board of directors said to ensure a quick technology installation at PX’Therapeutics Ribovax used the professional services of Solid Drug Development, an operational consultancy company founded by Ribovax’s previous CEO, Jean-Marc Combette.